{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:41Z","timestamp":1793726081846,"version":"4.6.1"},"reference-count":542,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["K12-HD105271"],"award-info":[{"award-number":["K12-HD105271"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005347","name":"American Association for the Study of Liver Diseases","doi-asserted-by":"publisher","award":["PNC22-159963"],"award-info":[{"award-number":["PNC22-159963"]}],"id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020172","name":"San Diego Digestive Diseases Research Center, School of Medicine, University of California, San Diego","doi-asserted-by":"publisher","award":["P30-DK120515"],"award-info":[{"award-number":["P30-DK120515"]}],"id":[{"id":"10.13039\/100020172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","award":["KL2TR001444"],"award-info":[{"award-number":["KL2TR001444"]}],"id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.pharmr.2025.100058","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:43:13Z","timestamp":1744803793000},"page":"100058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antiobesity medications in adult and pediatric obesity and metabolic dysfunction\u2013associated steatotic liver disease"],"prefix":"10.1016","volume":"77","author":[{"given":"Natalie","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3658-3335","authenticated-orcid":false,"given":"Phillipp","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmr.2025.100058_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib2","first-page":"234","article-title":"An evaluation of behavioral techniques reinforced with an anorectic drug in a double-blind weight loss study","volume":"41","author":"Abramson","year":"1980","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmr.2025.100058_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/obr.12111","article-title":"Association of run-in periods with weight loss in obesity randomized controlled trials","volume":"15","author":"Affuso","year":"2014","journal-title":"Obes Rev"},{"key":"10.1016\/j.pharmr.2025.100058_bib426","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":"The pharmacokinetics pharmacodynamics safety and toleratibility of NN2211 a new long-acting GLP-1 derivative in healthy men","volume":"45","author":"Agers\u00f8","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib4","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.2337\/db10-1740","article-title":"GLUT2 accumulation in enterocyte apical and intracellular membranes: a study in morbidly obese human subjects and ob\/ob and high fat-fed mice","volume":"60","author":"Ait-Omar","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin Obes"},{"key":"10.1016\/j.pharmr.2025.100058_bib6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jgh.12116","article-title":"Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study","volume":"28","author":"Alexander","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib7","unstructured":"Alli (orlistat) capsules. (2022) Package insert. US Food and Drug Administration. Revised December 2022. Accessed May 15, 2023. GSK Consumer Healthcare, Warren, NJ."},{"key":"10.1016\/j.pharmr.2025.100058_bib8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib419","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/jdi.13962","article-title":"Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion in humans: Characteristics and regulation","volume":"14","author":"Alsalim","year":"2023","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.pharmr.2025.100058_bib9","first-page":"S1","article-title":"Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"10","author":"Amiri Dash Atan","year":"2017","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"10.1016\/j.pharmr.2025.100058_bib11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/000992286700600607","article-title":"Treatment of obesity in underprivileged adolescents. Comparison of diethylpropion hydrochloride with placebo in a double-blind study","volume":"6","author":"Andelman","year":"1967","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.pharmr.2025.100058_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140908","article-title":"The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis","volume":"10","author":"Anderson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100058_bib13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/07315724.1999.10718897","article-title":"Long-term weight maintenance after an intensive weight-loss program","volume":"18","author":"Anderson","year":"1999","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.pharmr.2025.100058_bib420","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib421","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1007\/s00125-016-4033-1","article-title":"Transcriptomic profiling of pancreatic alpha beta and delta cell populations identifies delta cells as a principal target for ghrelin in mousse islets","volume":"59","author":"Adriaenssens","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib422","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1471-4159.2005.03259.x","article-title":"Topiramate reduces AMP-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures","volume":"94","author":"Angehagen","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmr.2025.100058_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MEG.0000000000001369","article-title":"Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial","volume":"31","author":"Anushiravani","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/M18-1605","article-title":"Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes study","volume":"170","author":"Apolzan","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2009.11.019","article-title":"Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes","volume":"123","author":"Apovian","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0074-7742(09)88009-4","article-title":"Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion","volume":"88","author":"Arias","year":"2009","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.pharmr.2025.100058_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib423","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes PIONEER PLUS a multicentre randomized phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib424","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides SNAC and the development of the oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.pharmr.2025.100058_bib22","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2015-3754","article-title":"Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study","volume":"101","author":"Aroda","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib23","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib24","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/oby.2009.478","article-title":"Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial","volume":"18","author":"Aronne","year":"2010","journal-title":"Obesity"},{"key":"10.1016\/j.pharmr.2025.100058_bib425","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"Suppl_1","key":"10.1016\/j.pharmr.2025.100058_bib25","article-title":"262-OR: pemvidutide, a GLP-1\/glucagon dual receptor agonist, in subjects with overweight or obesity\u2014a 48-week, placebo-controlled, phase 2 (MOMENTUM) Trial","volume":"73","author":"Aronne","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib26","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa2204601","article-title":"Once-weekly dulaglutide for the treatment of youths with type 2 diabetes","volume":"387","author":"Arslanian","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib28","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100058_bib427","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ijo.2013.73","article-title":"Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal subcutaenous adipose tissue metabolism in obese subjects","volume":"38","author":"Asmar","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib428","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/jc.2016-1933","article-title":"Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans","volume":"101","author":"Asmar","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib429","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2337\/db10-0098","article-title":"Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans","volume":"59","author":"Asmar","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib30","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/oby.2004.206","article-title":"Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects","volume":"12","author":"Astrup","year":"2004","journal-title":"Obes Res"},{"key":"10.1016\/j.pharmr.2025.100058_bib31","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib32","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00125-008-1053-5","article-title":"Metformin and the intestine","volume":"51","author":"Bailey","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/dom.14284","article-title":"Extended-release naltrexone\/bupropion and liver health: pooled, post hoc analysis from four randomized controlled trials","volume":"23","author":"Bajaj","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib34","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1097\/00004872-200211000-00026","article-title":"Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension","volume":"20","author":"Bakris","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmr.2025.100058_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.metabol.2018.03.017","article-title":"Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: a randomized, double-blind, placebo-controlled trial","volume":"85","author":"Basolo","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2025.100058_bib36","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.molmet.2017.07.016","article-title":"Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease","volume":"6","author":"Baumeier","year":"2017","journal-title":"Mol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3945\/ajcn.110.004895","article-title":"Is lost lean mass from intentional weight loss recovered during weight regain in postmenopausal women?","volume":"94","author":"Beavers","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.pharmr.2025.100058_bib431","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100058_bib38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1996.tb00606.x","article-title":"Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures","volume":"37","author":"Ben-Menachem","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmr.2025.100058_bib39","unstructured":"Benzphetamine hydrochloride tablet (2021) Package insert. US Food and Drug Administration. Revised January 2021. Accessed May 15, 2023. Epic Pharma, Laurelton, NY."},{"key":"10.1016\/j.pharmr.2025.100058_bib432","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097051","article-title":"Inter-species cross-seeding: stability and assembly of rat-human amylin aggregates","volume":"9","author":"Berhanu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100058_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087488","article-title":"Glucose-induced glucagon-like peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease","volume":"9","author":"Bernsmeier","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100058_bib41","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0133-24.2024","article-title":"Ventral tegmental area amylin receptor activation differentially modulates mesolimbic dopamine signaling in response to fat versus sugar","volume":"11","author":"Bhimani","year":"2024","journal-title":"eNeuro"},{"key":"10.1016\/j.pharmr.2025.100058_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00125-019-05021-6","article-title":"Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation","volume":"63","author":"Bizino","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib43","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2025.100058_bib44","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/ADM.0000000000000206","article-title":"Abuse potential of oral phendimetrazine in cocaine-dependent individuals: implications for agonist-like replacement therapy","volume":"10","author":"Bolin","year":"2016","journal-title":"J Addict Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib46","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/dom.14465","article-title":"Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD-11","volume":"23","author":"Bonora","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib47","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/dom.13567","article-title":"Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes","volume":"21","author":"Borg","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib438","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1530\/JOE-18-0264","article-title":"Are peptide conjugates the golden therapy against obesity?","volume":"238","author":"Brandt","year":"2018","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100058_bib48","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/edrv.20.6.0383","article-title":"Current and potential drugs for treatment of obesity","volume":"20","author":"Bray","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmr.2025.100058_bib439","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A 6-month randomized placebo-controlled dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"},{"key":"10.1016\/j.pharmr.2025.100058_bib49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","article-title":"Central and peripheral GLP-1 systems independently suppress eating","volume":"3","author":"Brierley","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1742-1241.2002.tb11307.x","article-title":"Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study","volume":"56","author":"Broom","year":"2002","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pharmr.2025.100058_bib441","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1139\/y69-020","article-title":"Preparation of highly active enterogastrone","volume":"47","author":"Brown","year":"1969","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100058_bib440","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1139\/o71-122","article-title":"A gastric inhibitory polypeptide. II. The complete amino acid sequence","volume":"49","author":"Brown","year":"1971","journal-title":"Can J Biochem"},{"key":"10.1016\/j.pharmr.2025.100058_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00492251","article-title":"Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man","volume":"56","author":"Buchan","year":"1978","journal-title":"Histochemistry"},{"key":"10.1016\/j.pharmr.2025.100058_bib52","first-page":"37","article-title":"The appreciation of the medical profession and the divine origin of medicine","volume":"1","author":"Burger","year":"1929","journal-title":"Ann Med Hist"},{"key":"10.1016\/j.pharmr.2025.100058_bib53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF02595511","article-title":"\u00dcber das Glukagon (die hyperglyk\u00e4misierende Substanz des Pankreas)","volume":"96","author":"B\u00fcrger","year":"1935","journal-title":"Z Gesamte Exp Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib443","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2337\/diab.39.6.752","article-title":"Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans","volume":"39","author":"Butler","year":"1990","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib54","unstructured":"Byetta (exenatide) injection. (2022) Package insert. US Food and Drug Administration. Revised December 2022. Accessed May 15, 2023. AstraZeneca Pharmaceuticals, Wilmington, DE."},{"key":"10.1016\/j.pharmr.2025.100058_bib55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41366-021-01019-6","article-title":"Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience","volume":"46","author":"Calderon","year":"2022","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib56","first-page":"851","article-title":"A controlled trial of phentermine in obese diabetic patients","volume":"218","author":"Campbell","year":"1977","journal-title":"Practitioner"},{"key":"10.1016\/j.pharmr.2025.100058_bib57","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41590-019-0407-0","article-title":"Metabolic adaptations of tissue-resident immune cells","volume":"20","author":"Caputa","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pharmr.2025.100058_bib58","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1210\/en.2012-1272","article-title":"Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice","volume":"153","author":"Caricilli","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2025.100058_bib430","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jcem-39-2-223","article-title":"Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man","volume":"39","author":"Cataland","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib59","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ijo.2009.124","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects","volume":"33","author":"Cercato","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib60","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100058_bib61","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s13139-020-00647-6","article-title":"Association between colonic 18F-FDG uptake and glycemic control in patients with diabetes mellitus","volume":"54","author":"Chang","year":"2020","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.pharmr.2025.100058_bib62","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12902-022-01046-y","article-title":"Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged \u226540 years","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.pharmr.2025.100058_bib64","article-title":"Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus","volume":"15","author":"Chen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100058_bib65","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jama.1926.02680110036011","article-title":"The action and clincal use of ephedrine: an alkaloid isolated from the Chinese drug ma huang","volume":"87","author":"Chen","year":"1926","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pharmr.2025.100058_bib433","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134359","article-title":"Leptin receptor-expressing nucleus tractus solitarius neurons suppress food intake independently of GLP1 in mice","volume":"5","author":"Cheng","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmr.2025.100058_bib66","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2337\/db08-0958","article-title":"Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes","volume":"58","author":"Chia","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib67","first-page":"155","article-title":"Double-blind, parallel-group, placebo-controlled multi-center clinical trial for evaluating the efficacy and safety of phentermine hydrochloride in obese patients","volume":"14","author":"Choi","year":"2005","journal-title":"Korean J Obes"},{"key":"10.1016\/j.pharmr.2025.100058_bib68","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib69","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hep.26606","article-title":"Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides","volume":"59","author":"Cinar","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100058_bib71","unstructured":"Contrave (naltrexone HCL and bupropion HCL) extended-release tablets. (2021) Package insert. US Food and Drug Administration. Revised March 2021. Accessed May 15, 2023. Nalpropion Pharmaceuticals, La Jolla, CA."},{"key":"10.1016\/j.pharmr.2025.100058_bib434","first-page":"391","article-title":"Delayed manifestation of the physiological effects of insulin following the administration of certain pancreatic extracts","volume":"63","author":"Collip","year":"1923","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmr.2025.100058_bib435","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of glucagon-like peptide-1 receptor expresssing cells in the mouse brain","volume":"4","author":"Cork","year":"2015","journal-title":"Mol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib436","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176 a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib70","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmr.2025.100058_bib72","first-page":"2381","article-title":"Phentermine\u2014resin or salt\u2014 there are differences","volume":"157","author":"Coyne","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib437","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00429703","article-title":"Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels","volume":"14","author":"Creutzfeldt","year":"1978","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib73","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib74","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.pharmr.2025.100058_bib75","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib76","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.2147\/DMSO.S381652","article-title":"Use of contrave, naltrexone with bupropion, bupropion, or naltrexone and major adverse cardiovascular events: a systematic literature review","volume":"15","author":"Dahlberg","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.pharmr.2025.100058_bib442","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1172\/JCI91761","article-title":"Age-dependent human \u03b2 cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling","volume":"127","author":"Dai","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib77","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpeds.2016.10.076","article-title":"Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years","volume":"181","author":"Danne","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmr.2025.100058_bib78","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib79","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib80","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib445","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00125-008-1149-y","article-title":"Glucagon-like peptide-1 but not glucose-dependent insulinotropic peptide inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas","volume":"51","author":"de Heer","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib82","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib447","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib83","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jcem-73-6-1294","article-title":"Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects","volume":"73","author":"DeFronzo","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib448","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance lipotoxicity type 2 diabetes and atherosclerosis the timing links the Claude Bernard lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib84","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1139\/cjpp-2012-0300","article-title":"Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy","volume":"91","author":"Derosa","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100058_bib451","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/dia.2011.0050","article-title":"Encapsulation of exenatide in poly-(D L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes","volume":"13","author":"DeYoung","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib85","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.numecd.2018.08.007","article-title":"Preclinical signs of liver and cardiac damage in youth with metabolically healthy obese phenotype","volume":"28","author":"Di Bonito","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.pharmr.2025.100058_bib86","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dc11-1299","article-title":"Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib87","unstructured":"Diethylpropion hydrochloride extended release tablet. (2019a) Package insert. US Food and Drug Administration. Revised December 2019. Accessed May 15, 2023. Lannett Company, Philadelphia, PA."},{"key":"10.1016\/j.pharmr.2025.100058_bib88","unstructured":"Diethylpropion hydrochloride tablet. (2019b) Package insert. US Food and Drug Administration. Revised December 2019. Accessed May 15, 2023. Lannett Company, Philadelphia, PA."},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2025.100058_bib453","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1528-1157.2000.tb02169.x","article-title":"Topiramate as an inhibitor of carbonic anhydrase isoenzymes","volume":"41","author":"Dodgson","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmr.2025.100058_bib454","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib90","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib91","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib92","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1499-3872(11)60120-3","article-title":"Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"11","author":"Duan","year":"2012","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.pharmr.2025.100058_bib458","doi-asserted-by":"crossref","first-page":"R856","DOI":"10.1152\/ajpregu.00179.2018","article-title":"Rodent models of leptin deficiency are less sensitive to amylin","volume":"315","author":"Duffy","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharmr.2025.100058_bib93","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.nutr.27.061406.093734","article-title":"Regulation of lipolysis in adipocytes","volume":"27","author":"Duncan","year":"2007","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.pharmr.2025.100058_bib459","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2337\/diab.15.8.555","article-title":"Stimulation of release of insulin by an extract of intestinal mucosa","volume":"15","author":"Dupre","year":"1966","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib460","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib94","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib461","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00257346","article-title":"Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) form rat gut extracts by immunoadsorption","volume":"24","author":"Ebert","year":"1983","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib95","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/rr181","article-title":"Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis","volume":"3","author":"Eddahibi","year":"2002","journal-title":"Respir Res"},{"key":"10.1016\/j.pharmr.2025.100058_bib462","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2362.1992.tb01464.x","article-title":"Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat pig and man","volume":"22","author":"Eissele","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib96","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100058_bib463","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf1948","article-title":"GIP mediates the incretin effect and glucose tolerance by dual actions on \u03b1 cells and \u03b2 cells","volume":"7","author":"El","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.pharmr.2025.100058_bib97","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"5","author":"El","year":"2023","journal-title":"Nat Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib98","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11695-020-04987-2","article-title":"Pharmacotherapy for obesity-trends using a population level national database","volume":"31","author":"Elangovan","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.pharmr.2025.100058_bib464","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/sj.ijo.0803548","article-title":"Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients randomized double-blind placebo-controlled trial","volume":"31","author":"Eliasson","year":"2007","journal-title":"Int J Obes"},{"key":"10.1016\/j.pharmr.2025.100058_bib102","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Plasma insulin response to oral and intravenous glucose administration","volume":"24","author":"Elrick","year":"1964","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib465","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety tolerability pharmacokinetics and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised controlled phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib103","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100058_bib104","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/ijc.25797","article-title":"Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis","volume":"128","author":"Ertle","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmr.2025.100058_bib105","unstructured":"European Medicines Agency (2009) Public statement on Acomplia (rimonabant) withdrawal of the marketing authorisation in the European Union (Wathion NL ed), EMA, London."},{"key":"10.1016\/j.pharmr.2025.100058_bib444","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2265.1980.tb03427.x","article-title":"The effect of increasing doses of ingested glucose on insulin and gastric inhibitory polypeptide (GIP) concentration in man","volume":"13","author":"Falko","year":"1980","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100058_bib106","series-title":"Guidance for Industry Developing Products for Weight Management","year":"2007"},{"key":"10.1016\/j.pharmr.2025.100058_bib446","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0014-5793(89)80899-3","article-title":"Synergistic stimulatory effect of glucagon-like peptide-1 (7-36) amide and glucose-dependent insulin-releasing polypeptide on the endocrine rat pancreas","volume":"252","author":"Fehmann","year":"1989","journal-title":"FEBS letters"},{"key":"10.1016\/j.pharmr.2025.100058_bib107","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2014.05.016","article-title":"Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats","volume":"737","author":"Feigh","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100058_bib108","first-page":"408","article-title":"Phenmetrazine hydrochloride; a clinical evaluation of a new anoretic agent","volume":"87","author":"Feldman","year":"1957","journal-title":"Calif Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib109","unstructured":"Fendique ER (phendimetrazine tartrate) extended-release capsules. (2019) Package insert. US Food and Drug Administration. Revised March 2019. Accessed May 15, 2023. Virtus Pharmaceuticals, Langhorne, PA."},{"key":"10.1016\/j.pharmr.2025.100058_bib110","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2165\/00003495-200262060-00005","article-title":"Pharmacological approaches for the treatment of obesity","volume":"62","author":"Fern\u00e1ndez-L\u00f3pez","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.pharmr.2025.100058_bib449","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents monkeys and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib450","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib112","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2012.39","article-title":"Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010","volume":"307","author":"Flegal","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib452","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib113","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib114","series-title":"Clinical Briefing Document, Endocrine and Metabolic Drugs Advisory Committee Meeting","article-title":"New drug application 22580: VI-052 Qnexa (phentermine\/topiramate)","year":"2012"},{"key":"10.1016\/j.pharmr.2025.100058_bib115","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/oby.23395","article-title":"Exenatide for weight-loss maintenance in adolescents with severe obesity: a randomized, placebo-controlled trial","volume":"30","author":"Fox","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib116","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/oby.21633","article-title":"Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial","volume":"24","author":"Fox","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib455","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1017\/S0029665118002598","article-title":"Turning over our fat stores: the key to metabolic health Blaxter Award lecture 2018","volume":"78","author":"Frayn","year":"2019","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.pharmr.2025.100058_bib456","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dula GIP\/GLP-1 receptor agonist NNC0090-2746 in patient with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib457","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly 2.4 mg in type 2 diabetes a multicenter randomised double-blind active-controlled phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib117","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib118","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib119","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1111\/dom.13764","article-title":"Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin","volume":"21","author":"Frias","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.13053","article-title":"Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial","volume":"20","author":"Fr\u00f8ssing","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib121","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000497124","article-title":"The ABCD of obesity: An EASO position statement on a diagnostic term with clinical and scientific implications","volume":"12","author":"Fr\u00fchbeck","year":"2019","journal-title":"Obes Facts"},{"key":"10.1016\/j.pharmr.2025.100058_bib122","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2337\/dbi21-0001","article-title":"The role of GIP receptor in the CNS for the pathogenesis of obesity","volume":"70","author":"Fukuda","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib123","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/nm.3372","article-title":"Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin","volume":"19","author":"Fullerton","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib124","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/14656560902824152","article-title":"Combination pharmaceutical therapies for obesity","volume":"10","author":"Gadde","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharmr.2025.100058_bib125","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib126","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/dom.12908","article-title":"Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study","volume":"19","author":"Gadde","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib127","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib128","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE Insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib129","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib130","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib131","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.pharmr.2025.100058_bib466","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib132","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2007.04.068","article-title":"Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects","volume":"133","author":"Gastaldelli","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib468","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1172\/JCI81335","article-title":"Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight","volume":"127","author":"Gaykema","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib469","first-page":"R116","article-title":"Glucagon acts in the liver to control spontaneous meal size in rats","volume":"264","author":"Geary","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmr.2025.100058_bib470","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0026-0495(97)90170-0","article-title":"Dose-response for glucagonostatis effect of amylin in rats","volume":"46","author":"Gedulin","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2025.100058_bib133","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-16-0513","article-title":"Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones","volume":"234","author":"Geisler","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100058_bib134","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1517\/13543784.15.3.307","article-title":"Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors","volume":"15","author":"Gelfand","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmr.2025.100058_bib135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1074248413501017","article-title":"New and emerging drug molecules against obesity","volume":"19","author":"George","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib136","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib471","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41580-018-0093-z","article-title":"Adipogenesis and metabolic health","volume":"20","author":"Ghaben","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.pharmr.2025.100058_bib137","unstructured":"Glumeteza (metformin hydrochloride) extended-release tablets. (2018) Package insert. US Food and Drug Administration. Revised May 2018. Accessed May 15, 2023. Salix Pharmaceuticals, Bridgewater, NJ."},{"key":"10.1016\/j.pharmr.2025.100058_bib138","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41366-020-0544-4","article-title":"The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database","volume":"44","author":"Gorelik","year":"2020","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib139","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2967\/jnumed.116.177774","article-title":"In vivo imaging of human 11c-metformin in peripheral organs: dosimetry, biodistribution, and kinetic analyses","volume":"57","author":"Gormsen","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/oby.22347","article-title":"A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss","volume":"27","author":"Greenway","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib142","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib143","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF02890341","article-title":"Cytochemical and ultrastructural differentiation of enteroglucagon and pancreatic-type glucagon cells of the gastrointestinal tract","volume":"20","author":"Grimelius","year":"1976","journal-title":"Virchows Arch B Cell Pathol"},{"key":"10.1016\/j.pharmr.2025.100058_bib144","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1464-5491.2012.03745.x","article-title":"Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study","volume":"29","author":"Grunberger","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib145","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib146","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.pharmr.2025.100058_bib147","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/dom.13266","article-title":"Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study","volume":"20","author":"Guja","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib148","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1542\/peds.2012-0596","article-title":"Clinical tracking of severely obese children: a new growth chart","volume":"130","author":"Gulati","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmr.2025.100058_bib149","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1462-8902.2004.00359.x","article-title":"Effects of orlistat on obesity-related diseases\u2014a six-month randomized trial","volume":"6","author":"Guy-Grand","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib150","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib151","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100058_bib152","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","article-title":"Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials","volume":"26","author":"Haddock","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.pharmr.2025.100058_bib153","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/j.1552-4604.1968.tb00256.x","article-title":"Sustained-action phendimetrazine in obesity","volume":"8","author":"Hadler","year":"1968","journal-title":"J Clin Pharmacol J New Drugs"},{"key":"10.1016\/j.pharmr.2025.100058_bib154","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/bj2560357","article-title":"Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin","volume":"256","author":"Hadv\u00e1ry","year":"1988","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmr.2025.100058_bib155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/1389450043490541","article-title":"The pharmacology of human appetite expression","volume":"5","author":"Halford","year":"2004","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.pharmr.2025.100058_bib156","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmr.2025.100058_bib467","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1124\/jpet.114.220350","article-title":"Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers","volume":"352","author":"Han","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib157","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jpeds.2018.02.038","article-title":"Clinically actionable hypercholesterolemia and hypertriglyceridemia in children with nonalcoholic fatty liver disease","volume":"198","author":"Harlow","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmr.2025.100058_bib158","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib159","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cld.685","article-title":"Risk factors for progression of and treatment options for NAFLD in children","volume":"11","author":"Hartmann","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.pharmr.2025.100058_bib160","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/HEP.0000000000000383","article-title":"Global and national prevalence of nonalcoholic fatty liver disease in adolescents: an analysis of the global burden of disease study 2019","volume":"78","author":"Hartmann","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100058_bib161","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.pharmr.2025.100058_bib163","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmr.2025.100058_bib164","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/jdi.13110","article-title":"Glutaminostatin: another facet of glucagon as a regulator of plasma amino acid concentrations","volume":"10","author":"Hayashi","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.pharmr.2025.100058_bib165","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0269881113482532","article-title":"Amphetamine, past and present\u2014a pharmacological and clinical perspective","volume":"27","author":"Heal","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmr.2025.100058_bib166","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","article-title":"Orlistat, a new lipase inhibitor for the management of obesity","volume":"20","author":"Heck","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmr.2025.100058_bib472","first-page":"116","article-title":"Reactions of the two types of A cells in the islets of langerhans after administration of glucagon","volume":"41","author":"Hellerstrom","year":"1962","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.pharmr.2025.100058_bib167","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MJT.0b013e3181d070d7","article-title":"A study of abrupt phentermine cessation in patients in a weight management program","volume":"18","author":"Hendricks","year":"2011","journal-title":"Am J Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib168","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/oby.2011.94","article-title":"Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity","volume":"19","author":"Hendricks","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib169","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ijo.2013.74","article-title":"Addiction potential of phentermine prescribed during long-term treatment of obesity","volume":"38","author":"Hendricks","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib170","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1517\/14712598.2010.526104","article-title":"Oral salmon calcitonin\u2014pharmacology in osteoporosis","volume":"10","author":"Henriksen","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib171","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1111\/bcp.14921","article-title":"Safety, tolerability and pharmacokinetic characterisation of DACRA KBP-042 in healthy male subjects","volume":"87","author":"Henriksen","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100058_bib172","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of Bimagrumab on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pharmr.2025.100058_bib173","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2007.03.025","article-title":"Impact of diabetes on the severity of liver disease","volume":"120","author":"Hickman","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib175","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/oby.21563","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity","volume":"24","author":"Hjuler","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101590","article-title":"GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein","volume":"65","author":"Hoffman","year":"2022","journal-title":"Mol Metab"},{"issue":"Suppl 3","key":"10.1016\/j.pharmr.2025.100058_bib177","first-page":"35","article-title":"Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase","volume":"11","author":"Hogan","year":"1987","journal-title":"Int J Obes"},{"key":"10.1016\/j.pharmr.2025.100058_bib475","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib178","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc16-2427","article-title":"Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial","volume":"40","author":"Hollander","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib179","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib181","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmr.2025.100058_bib478","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib479","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2337\/db18-0729","article-title":"Preproglucagon neuron in the nucleus of the solitary tract are the main source of brain GLP-1 mediate stress-induced hypophagia and limit unusually large intakes of food","volume":"68","author":"Holt","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib182","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.tem.2022.07.001","article-title":"Immune-metabolic interactions in homeostasis and the progression to NASH","volume":"33","author":"Hoogerland","year":"2022","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib183","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cmet.2016.12.009","article-title":"Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex","volume":"25","author":"Howell","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib184","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/dom.13910","article-title":"A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine\/topiramate in adolescents with obesity","volume":"22","author":"Hsia","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib185","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib482","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0168-8227(90)90043-S","article-title":"Amylin release from perfuse rat pancreas in response to glucose and arginine","volume":"10","author":"Inoue","year":"1990","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.pharmr.2025.100058_bib186","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib187","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013Hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2025.100058_bib188","article-title":"1866-LB: a phase 2 study of mazdutide 9 mg in Chinese adults with bmi of 30 kg\/m2 or more","volume":"73","author":"Jiang","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib189","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199809103391102","article-title":"A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation","volume":"339","author":"Jick","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib190","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2004.12.050","article-title":"Antifibrogenic role of the cannabinoid receptor CB2 in the liver","volume":"128","author":"Julien","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib191","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100058_bib192","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0031-9384(97)00545-3","article-title":"Evidence that dark-phase hyperphagia induced by neurotoxin 6-hydroxydopamine may be due to decreased leptin and increased neuropeptide Y signaling","volume":"63","author":"Kalra","year":"1998","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pharmr.2025.100058_bib193","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.neuropharm.2004.02.010","article-title":"Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist","volume":"46","author":"Kaminski","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmr.2025.100058_bib194","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","article-title":"Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity","volume":"12","author":"Kang","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib491","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0014-5793(88)81063-9","article-title":"Identification and characterization of glucagon-like peptide-1 7-36 amide-binding site in the rat brain and lung","volume":"241","author":"Kanse","year":"1988","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmr.2025.100058_bib195","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib492","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1113\/jphysiol.2001.013358","article-title":"Effects of insulin on adipose tissue blood flow in man","volume":"540","author":"Karpe","year":"2002","journal-title":"J Physiol"},{"key":"10.1016\/j.pharmr.2025.100058_bib493","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970 an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100058_bib196","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2337\/diacare.27.1.33","article-title":"Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes","volume":"27","author":"Kelley","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib197","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib198","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity","volume":"1","author":"Kelly","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.pharmr.2025.100058_bib199","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamapediatrics.2013.1045","article-title":"The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial","volume":"167","author":"Kelly","year":"2013","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.pharmr.2025.100058_bib200","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1210\/jc.2012-2710","article-title":"Metformin in obese children and adolescents: the MOCA trial","volume":"98","author":"Kendall","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib495","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2025.100058_bib496","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2025.100058_bib201","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","article-title":"Effects on weight reduction and safety of short-term phentermine administration in Korean obese people","volume":"47","author":"Kim","year":"2006","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.pharmr.2025.100058_bib473","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1074\/jbc.M609088200","article-title":"Activation of lipoprotein lipase by glucose-dependent insulinotropic polupeptide in adipocytes a role for a protein kinase B LKB1 and AMP-activated protein kinase cascade","volume":"282","author":"Kim","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100058_bib474","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1194\/jlr.M012203","article-title":"Adipocute expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPAR\u03b3 and histone acetylation","volume":"52","author":"Kim","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmr.2025.100058_bib202","article-title":"GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100058_bib476","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0021-9258(18)85474-6","article-title":"Aqueous extracts of pancreas: III. some precipitation reactions of insulin","volume":"58","author":"Kimball","year":"1923","journal-title":"J of Biological Chem"},{"key":"10.1016\/j.pharmr.2025.100058_bib203","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1542\/peds.2008-3750","article-title":"A pilot trial of pramlintide home usage in adolescents with type 1 diabetes","volume":"124","author":"Kishiyama","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmr.2025.100058_bib477","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.749607","article-title":"Loss of function glucose-dependent insulinotropic polypeptide receptor variants are associated with alterations in BMI bone strength and cardiovascular outcomes","volume":"9","author":"Kizilkaya","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.pharmr.2025.100058_bib204","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100058_bib205","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pharmr.2025.100058_bib206","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib480","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pharmr.2025.100058_bib207","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.27981","article-title":"Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study","volume":"63","author":"Koehler","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100058_bib481","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces prostprandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib208","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/oby.21076","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk in children with obesity","volume":"23","author":"Koot","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib209","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/oby.20173","article-title":"Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children","volume":"21","author":"Koot","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib483","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3181\/00379727-27-5024","article-title":"Demonstration of the humoral agent in fat inhibition of gastric secretion","volume":"27","author":"Kosaka","year":"1930","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"10.1016\/j.pharmr.2025.100058_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154455","article-title":"The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"115","author":"Koutoukidis","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2025.100058_bib211","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/oby.2010.21","article-title":"Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program","volume":"18","author":"Krakoff","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib212","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/j.1467-789X.2010.00846.x","article-title":"Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials","volume":"12","author":"Kramer","year":"2011","journal-title":"Obes Rev"},{"key":"10.1016\/j.pharmr.2025.100058_bib213","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.ijo.0802281","article-title":"Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity","volume":"27","author":"Krempf","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.pharmr.2025.100058_bib214","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib484","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0006-8993(89)90628-8","article-title":"Characterization of glucagon-like peptide-1-1(7-36)amide in the hypothalamus","volume":"502","author":"Kreymann","year":"1989","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmr.2025.100058_bib485","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of Cagrilintide a long-acting amylin analogue","volume":"84","author":"Kruse","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100058_bib215","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172628","article-title":"Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications","volume":"862","author":"Kumawat","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100058_bib486","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2170\/jjphysiol.29.683","article-title":"Thermogenic responses of brown adipocytes to noradrenaline and glucagon in heat-acclimated and cold-acclimated rats","volume":"29","author":"Kuroshima","year":"1979","journal-title":"Jpn J Physiol"},{"key":"10.1016\/j.pharmr.2025.100058_bib487","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0016-5085(74)80134-4","article-title":"Radioimmunoassay for gastric inhibitory polypeptide","volume":"66","author":"Kuzio","year":"1974","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib217","first-page":"289","article-title":"A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity","volume":"16","author":"Langlois","year":"1974","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.pharmr.2025.100058_bib218","first-page":"16","article-title":"Pancreatic \u03b1-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation","volume":"2016","author":"Larger","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.pharmr.2025.100058_bib488","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.2337\/diabetes.50.11.2530","article-title":"Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats","volume":"50","author":"Larsen","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib489","first-page":"18","article-title":"Efficacy and safety of AM833 for weight loss: a dose-finding trial in adults with overweight\/obesity","volume":"28","author":"Lau","year":"2020","journal-title":"Obesity"},{"key":"10.1016\/j.pharmr.2025.100058_bib490","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3109\/00365528009181797","article-title":"The association between plasma GIP and insulin after oral glucose","volume":"15","author":"Lauritsen","year":"1980","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.pharmr.2025.100058_bib219","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib220","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib221","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100058_bib222","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jama.1959.03000250112027","article-title":"The amphetamines: their actions and uses","volume":"169","author":"Leake","year":"1959","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib223","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1370\/afm.1174","article-title":"Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus","volume":"8","author":"Lee","year":"2010","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib224","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/oby.22430","article-title":"Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort","volume":"27","author":"Lewis","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib494","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.metabol.2006.06.013","article-title":"The messenger RNA profiles in liver hypothalamus white adipose tissue and skeletal female zucker diabetic fatty rats after topiramate treatment","volume":"55","author":"Liang","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2025.100058_bib225","first-page":"620","article-title":"[Hunger control with benzphetamine hydrochloride in the treatment of obesity]","volume":"16","author":"Linquette","year":"1971","journal-title":"Lille Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib226","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.01.032","article-title":"Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice","volume":"142","author":"Liu","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib497","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neuroscience.2012.09.071","article-title":"Preproglucagon (PPG) neurons innervate neurochemically identified autonomic neurons in the mouse brainstem","volume":"229","author":"Llewellyn-Smith","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmr.2025.100058_bib227","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib228","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib229","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/adc.41.217.309","article-title":"Obesity in childhood. A controlled trial of anorectic drugs","volume":"41","author":"Lorber","year":"1966","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.pharmr.2025.100058_bib501","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.3714","article-title":"Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance","volume":"49","author":"Lotta","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmr.2025.100058_bib230","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jpeds.2008.01.018","article-title":"Addition of metformin to a lifestyle modification program in adolescents with insulin resistance","volume":"152","author":"Love-Osborne","year":"2008","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmr.2025.100058_bib231","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bmcl.2008.12.059","article-title":"Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice","volume":"19","author":"LoVerme","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharmr.2025.100058_bib504","article-title":"GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys","volume":"2","author":"Lu","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib505","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diab.40.12.1615","article-title":"Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes","volume":"40","author":"Ludvik","year":"1991","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib506","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/BF00285291","article-title":"Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets","volume":"32","author":"Lukinius","year":"1989","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib507","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/0006-291X(81)90709-9","article-title":"Intestinal glucagon mRNA identified by hybridization to a cloned islet cDNA encoding a precursor","volume":"100","author":"Lund","year":"1981","journal-title":"Biochem and Biophys Res Comm"},{"key":"10.1016\/j.pharmr.2025.100058_bib232","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib233","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(70)92126-4","article-title":"Treatment of hypoglycaemic coma with glucagon, intravenous dextrose, and mannitol infusion in a hundred diabetics","volume":"2","author":"MacCuish","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib509","doi-asserted-by":"crossref","first-page":"52446","DOI":"10.1074\/jbc.M307612200","article-title":"Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP\/protein kinase A and phosphatidylinositol 3-kinase signaling pathways","volume":"278","author":"MacDonald","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100058_bib235","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.appet.2011.06.017","article-title":"Alpha1 receptor antagonist in the median raphe nucleus evoked hyperphagia in free-feeding rats","volume":"57","author":"Mansur","year":"2011","journal-title":"Appetite"},{"key":"10.1016\/j.pharmr.2025.100058_bib236","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.diabet.2019.11.004","article-title":"Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib510","first-page":"179","article-title":"Action of various stimuli (galactose fructose and lipids) on human insulin secretion: influence on the gastrointestinal tract","volume":"10","author":"Marks","year":"1969","journal-title":"Journ Annu Diabetol Hotel Dieu"},{"key":"10.1016\/j.pharmr.2025.100058_bib237","series-title":"Prescription Drug Use in the United States, 2015\u20132016. NCHS Data Brief No 334","author":"Martin","year":"2019"},{"key":"10.1016\/j.pharmr.2025.100058_bib238","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.cub.2024.02.074","article-title":"A brainstem to hypothalamic arcuate nucleus GABAergic circuit drives feeding","volume":"34","author":"Martinez de Morentin","year":"2024","journal-title":"Curr Biol"},{"key":"10.1016\/j.pharmr.2025.100058_bib239","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1004128","article-title":"Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease","volume":"13","author":"Maruszczak","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pharmr.2025.100058_bib240","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/jm00388a023","article-title":"Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds","volume":"30","author":"Maryanoff","year":"1987","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100058_bib514","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2174\/156802609789630938","article-title":"Sugar sulfamates for seizure control: discovery and development of topiramate, a structurally unique antiepileptic drug","volume":"9","author":"Maryanoff","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.pharmr.2025.100058_bib241","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12495","article-title":"Liraglutide effects in a paediatric (7-11 y) population with obesity: a randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"14","author":"Mastrandrea","year":"2019","journal-title":"Pediatr Obes"},{"key":"10.1016\/j.pharmr.2025.100058_bib518","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2337\/dc13-1283","article-title":"GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance","volume":"37","author":"Matikainen","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib243","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dom.13487","article-title":"Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study","volume":"21","author":"Matikainen","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib244","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.tem.2015.07.007","article-title":"The endocannabinoid system: pivotal orchestrator of obesity and metabolic disease","volume":"26","author":"Mazier","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib245","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1592\/phco.22.11.814.33627","article-title":"Effects of orlistat on fat-soluble vitamins in obese adolescents","volume":"22","author":"McDuffie","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmr.2025.100058_bib246","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153732","article-title":"Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide","volume":"6","author":"McLean","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmr.2025.100058_bib519","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2337\/db10-0867","article-title":"Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for extopic fat deposition?","volume":"60","author":"McQuaid","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib247","first-page":"437","article-title":"Clinical assessment of the use of an anorectic drug in a total weight reduction program","volume":"17","author":"McQuarrie","year":"1975","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.pharmr.2025.100058_bib520","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/db10-1332","article-title":"GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglucemia patients with type 2 diabetes","volume":"60","author":"Mentis","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib521","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system","volume":"403","author":"Merchenthaler","year":"1999","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pharmr.2025.100058_bib248","unstructured":"Metformin hydrochloride tablet. (2022) Package insert. US Food and Drug Administration. Revised December 2022. Accessed May 15, 2023. ScieGen Pharmaceuticals, Hauppauge, NY."},{"key":"10.1016\/j.pharmr.2025.100058_bib249","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.physbeh.2016.02.034","article-title":"Amylin-mediated control of glycemia, energy balance, and cognition","volume":"162","author":"Mietlicki-Baase","year":"2016","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pharmr.2025.100058_bib250","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.pharmr.2025.100058_bib251","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib498","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib499","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s005350050184","article-title":"Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon","volume":"33","author":"Mochiki","year":"1998","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.pharmr.2025.100058_bib252","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12072-015-9679-0","article-title":"Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis","volume":"10","author":"Mohamad","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.pharmr.2025.100058_bib500","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/MCB.00256-14","article-title":"A naturally occurring GIP receptor variant undergoes enhanced agonnist-induced desensitization which impairs GIP control of adipose insulin sensitivity","volume":"34","author":"Mohammad","year":"2014","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmr.2025.100058_bib253","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib254","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/oby.21649","article-title":"Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings","volume":"24","author":"Moldovan","year":"2016","journal-title":"Obesity"},{"key":"10.1016\/j.pharmr.2025.100058_bib502","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1042\/bj0010028","article-title":"On the treatment of diabetus mellitus by acid extract of duodenal mucous membrane","volume":"1","author":"Moore","year":"1906","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmr.2025.100058_bib255","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity","volume":"1","author":"Munro","year":"1968","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmr.2025.100058_bib503","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db07-1315","article-title":"Separate impact of obesity and glucose tolerance on the increatin effect in normal sujects and type 2 diabetic patients","volume":"57","author":"Muscelli","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib256","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib257","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1399-5448.2008.00450.x","article-title":"Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents","volume":"10","author":"Nadeau","year":"2009","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib508","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.ijo.0800818","article-title":"Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men","volume":"23","author":"Naslund","year":"1999","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.pharmr.2025.100058_bib258","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib259","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib260","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib261","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2016.1971","article-title":"Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease","volume":"170","author":"Newton","year":"2016","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.pharmr.2025.100058_bib262","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib263","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/hep.26465","article-title":"Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients","volume":"58","author":"Noureddin","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100058_bib511","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patient with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib264","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib512","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1172\/JCI140046","article-title":"Gs\/Gq signaling switch in \u03b2 cells defines incretin effectiveness in diabetes","volume":"130","author":"Oduori","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib513","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1172\/JCI114528","article-title":"Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment","volume":"85","author":"Ogawa","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib265","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12916-016-0735-y","article-title":"Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib515","doi-asserted-by":"crossref","first-page":"12826","DOI":"10.1016\/S0021-9258(18)51561-1","article-title":"Complete sequences of glucagon-like peptide-1 from human and pig small intestine","volume":"264","author":"Orskov","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100058_bib516","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glucine-extended glucagon-like peptide I in humans","volume":"43","author":"Orskov","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib517","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.physbeh.2007.03.017","article-title":"Modulation of the satiating effect of amylin by central ghrelin leptin and insulin","volume":"91","author":"Osto","year":"2007","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pharmr.2025.100058_bib266","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/bmj.2.5354.427","article-title":"Amphetamine and phenmetrazine addiction","volume":"2","author":"Oswald","year":"1963","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmr.2025.100058_bib267","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/ijms17081218","article-title":"The impact of nonalcoholic fatty liver disease on renal function in children with overweight\/obesity","volume":"17","author":"Pacifico","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100058_bib269","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11940-019-0558-1","article-title":"Current status of antiepileptic drugs as preventive migraine therapy","volume":"21","author":"Parikh","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.pharmr.2025.100058_bib270","first-page":"329","article-title":"Controlled-release diethylpropion hydrochloride used in a program for weight reduction","volume":"3","author":"Parsons","year":"1981","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib271","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.pharmr.2025.100058_bib272","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-4285","article-title":"Metformin for obesity in prepubertal and pubertal children: a randomized controlled trial","volume":"140","author":"Pastor-Villaescusa","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharmr.2025.100058_bib273","first-page":"S290","article-title":"Tirzepatide-induced weight loss in type 2 diabetes is independent of nausea, vomiting, or diarrhoea","volume":"65","author":"Patel","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib274","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2119\/molmed.2011.00149","article-title":"Cannabinoid receptor type I modulates alcohol-induced liver fibrosis","volume":"17","author":"Patsenker","year":"2011","journal-title":"Mol Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib522","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1055\/s-2007-979981","article-title":"Physiological effect of glucagon in human isolated adipocytes","volume":"27","author":"Perea","year":"1995","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pharmr.2025.100058_bib275","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000524805","article-title":"Effect of phentermine on hepatic steatosis in bariatric surgery: a pilot study","volume":"31","author":"P\u00e9rez-Cruz","year":"2022","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.pharmr.2025.100058_bib276","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1172\/JCI105685","article-title":"Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects","volume":"46","author":"Perley","year":"1967","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib277","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-020-2074-6","article-title":"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis","volume":"579","author":"Perry","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100058_bib523","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1528-1157.2001.18800.x","article-title":"Topiramate rapidly raises brain GABA in epilepsy patients","volume":"42","author":"Petroff","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmr.2025.100058_bib278","unstructured":"Phendimetrazine tartrate tablets. (2019) Package insert. US Food and Drug Administration. Revised January 2019. Accessed May 15, 2023. Elite Laboratories, Northvale, NJ."},{"key":"10.1016\/j.pharmr.2025.100058_bib279","unstructured":"Phentermine hydrochloride capsule (2017) Package insert. US Food and Drug Administration. Revised April 2017. Accessed May 15, 2023. Lannett Company, Lureltton, NY."},{"key":"10.1016\/j.pharmr.2025.100058_bib280","unstructured":"Phentermine hydrochloride capsules (2018) Package insert. US Food and Drug Administration. Revised December 2018. Accessed May 15, 2023. KVK-Tech, Newton, PA."},{"key":"10.1016\/j.pharmr.2025.100058_bib282","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib283","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/oby.2000.84","article-title":"Topiramate reduces energy and fat gains in lean (Fa\/?) and obese (fa\/fa) Zucker rats","volume":"8","author":"Picard","year":"2000","journal-title":"Obes Res"},{"key":"10.1016\/j.pharmr.2025.100058_bib285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41366-021-00955-7","article-title":"Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist","volume":"46","author":"Pontes-da-Silva","year":"2022","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib286","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.soard.2018.03.019","article-title":"ASMBS pediatric metabolic and bariatric surgery guidelines, 2018","volume":"14","author":"Pratt","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.pharmr.2025.100058_bib287","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100058_bib526","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2025.100058_bib527","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1152\/ajpendo.00242.2009","article-title":"Fatty acids induce amylin expression and secretion by pancreatic beta-cells","volume":"298","author":"Qi","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib288","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib289","unstructured":"Qsymia (phentermine and topiramate extended-release) (2022) Package insert. US Food and Drug Administration. Revised June 2022. Accessed May 15, 2023. Vivus, Campbell, CA."},{"key":"10.1016\/j.pharmr.2025.100058_bib528","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13852","article-title":"GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P\/Q-type Ca","volume":"6","author":"Ramracheya","year":"2018","journal-title":"Physiol Rep"},{"key":"10.1016\/j.pharmr.2025.100058_bib529","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s13340-019-00423-8","article-title":"The development of oral semaglutide an oral GLP-1 analog for the treatment of type 2 diabetes","volume":"11","author":"Rasmussen","year":"2020","journal-title":"Diabetol Int"},{"key":"10.1016\/j.pharmr.2025.100058_bib290","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1162\/JINH_a_00212","article-title":"Medical science and the military: the Allies\u2019 use of amphetamine during World War II","volume":"42","author":"Rasmussen","year":"2011","journal-title":"J Interdiscip Hist"},{"key":"10.1016\/j.pharmr.2025.100058_bib530","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1463-1326.2006.00589.x","article-title":"Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus","volume":"8","author":"Ratner","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib291","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib293","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3803\/EnM.2019.34.3.226","article-title":"Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective","volume":"34","author":"Rhee","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.pharmr.2025.100058_bib294","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1378\/chest.117.3.870","article-title":"Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension","volume":"117","author":"Rich","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.pharmr.2025.100058_bib531","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/db13-1440","article-title":"Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model","volume":"63","author":"Richards","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib295","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2337\/dbi22-0004","article-title":"The liver-\u03b1-cell axis in health and in disease","volume":"71","author":"Richter","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib297","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/cpt.2382","article-title":"Metformin stimulates intestinal glycolysis and lactate release: a single-dose study of metformin in patients with intrahepatic portosystemic stent","volume":"110","author":"Rittig","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib298","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib537","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41574-018-0020-6","article-title":"The somatostatin-secretin pancreatic \u03b4-cell in health and disease","volume":"14","author":"Rorsman","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100058_bib299","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib300","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib301","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib302","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group","volume":"8","author":"R\u00f6ssner","year":"2000","journal-title":"Obes Res"},{"key":"10.1016\/j.pharmr.2025.100058_bib303","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.0706473105","article-title":"Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies","volume":"105","author":"Roth","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100058_bib304","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/01.CIR.100.8.869","article-title":"Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension","volume":"100","author":"Rothman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100058_bib305","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MJT.0b013e31817fde95","article-title":"Appetite suppressants, cardiac valve disease and combination pharmacotherapy","volume":"16","author":"Rothman","year":"2009","journal-title":"Am J Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib306","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100058_bib308","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib524","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.regpep.2007.02.006","article-title":"GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women","volume":"142","author":"Rudovich","year":"2007","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmr.2025.100058_bib309","first-page":"270","article-title":"Observations on the use of phendimetrazine, a new anorexigenic agent, in obese diabetics","volume":"4","author":"Runyan","year":"1962","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.pharmr.2025.100058_bib525","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157515","article-title":"Suppression of food intake by Glp1r\/Lepr-coexpressing neurons prevents obesity in mouse models","volume":"133","author":"Rupp","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib310","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ijo.2016.185","article-title":"Effect of phentermine on weight reduction in a pediatric weight management clinic","volume":"41","author":"Ryder","year":"2017","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib311","unstructured":"Rybelsus (semaglutide) tablets. (2019) Package insert. US Food and Drug Administration. Revised September 2019. Accessed May 15, 2023. Novo Nordisk, Bagsvaerd, Denmark."},{"key":"10.1016\/j.pharmr.2025.100058_bib312","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002967.pub3","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"2010","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmr.2025.100058_bib313","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2337\/diab.15.12.855","article-title":"Interrelationship of glucagon, insulin and glucose. The insulinogenic effect of glucagon","volume":"15","author":"Samols","year":"1966","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib314","series-title":"American Diabetes Association 83rd Scientific Sessions","article-title":"Retatrutide in NAFLD\u2014phase 2 trial results in subset of patients with obesity and NAFLD","author":"Sanyal","year":"2023"},{"key":"10.1016\/j.pharmr.2025.100058_bib315","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmr.2025.100058_bib316","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib317","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib318","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1002\/oby.22581","article-title":"Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015","volume":"27","author":"Saxon","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib532","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00125-007-0753-6","article-title":"Impaired glucagon-like peptide 1-induced insulin secretion in carriers of trasncription factor 7-like 1 (TCF7L2)","volume":"50","author":"Schafer","year":"2007","journal-title":"Dibetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112569","article-title":"Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease","volume":"9","author":"Schwimmer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100058_bib321","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s42255-024-01018-7","article-title":"Metformin and feeding increase levels of the appetite-suppressing metabolite Lac-Phe in humans","volume":"6","author":"Scott","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib533","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm1196-1254","article-title":"Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene","volume":"2","author":"Scrocchi","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib534","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1210\/endo.139.7.6092","article-title":"Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -\/- mice","volume":"139","author":"Scrocchi","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2025.100058_bib535","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1517\/13543776.2013.790957","article-title":"Antiobesity carbonic anhydrase inhibitors: a literature and patent review","volume":"23","author":"Scozzafava","year":"2013","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.pharmr.2025.100058_bib536","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib322","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0306-4522(94)90388-3","article-title":"In vitro autoradiographic localization of amylin binding sites in rat brain","volume":"62","author":"Sexton","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmr.2025.100058_bib323","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1527-3458.2008.00041.x","article-title":"Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate","volume":"14","author":"Shank","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib324","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib538","doi-asserted-by":"crossref","first-page":"19333","DOI":"10.1073\/pnas.0707054104","article-title":"Essential role of Epac2\/Rap1 signaling in regulation of insulin granule dynamics by cAMP","volume":"104","author":"Shibasaki","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100058_bib325","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.xphs.2022.01.008","article-title":"Multiple transport mechanisms involved in the intestinal absorption of metformin: impact on the nonlinear absorption kinetics","volume":"111","author":"Shirasaka","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharmr.2025.100058_bib326","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1515\/jpem-2019-0546","article-title":"Trends in pediatric obesity management, a survey from the Pediatric Endocrine Society Obesity Committee","volume":"33","author":"Shoemaker","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib327","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2362.1992.tb01820.x","article-title":"Comparison of the effect of GIP and GLP-1 (7-36amide) on insulin release from rat pancreatic islets","volume":"22","author":"Siegel","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib328","first-page":"33","article-title":"A controlled clinical trial of benzphetamine (didrex) in the management of obesity","volume":"2","author":"Simkin","year":"1960","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.pharmr.2025.100058_bib329","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib539","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1172\/JCI72434","article-title":"Neuronal GLP1R mediates liraglutide\u2019s anorectic but not glucose-lowering effect","volume":"124","author":"Sisley","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100058_bib330","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib540","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ceca.2010.12.005","article-title":"cAMP increases the sensitivity of exocytosis to Ca2+ primarily through protein kinase A in mouse pancreatic beta cells","volume":"49","author":"Skelin","year":"2011","journal-title":"Cell Calcium"},{"key":"10.1016\/j.pharmr.2025.100058_bib331","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp5765","article-title":"The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron","volume":"16","author":"Sloop","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib332","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib333","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial","volume":"59","author":"Smits","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100058_bib334","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"GLP-1 agonists and gastrointestinal adverse events","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib335","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.metabol.2011.01.011","article-title":"Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial","volume":"60","author":"Sofer","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2025.100058_bib336","doi-asserted-by":"crossref","DOI":"10.1038\/srep31385","article-title":"Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters","volume":"6","author":"Solis","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2025.100058_bib545","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1053\/j.gastro.2007.09.005","article-title":"Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation","volume":"133","author":"Song","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib337","first-page":"351","article-title":"Effects of diet, exercise and anorexigenic drugs on serum thyroid hormones","volume":"76","author":"Sonka","year":"1980","journal-title":"Endokrinologie"},{"key":"10.1016\/j.pharmr.2025.100058_bib338","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5414\/CP202135","article-title":"Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial","volume":"53","author":"Soto-Molina","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib547","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bcp.2017.02.012","article-title":"GIP(3-30)NH","volume":"131","author":"Sparre-Ulrich","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100058_bib339","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5694\/j.1326-5377.1969.tb92170.x","article-title":"Double-blind trial of anorectic agents","volume":"1","author":"Sproule","year":"1969","journal-title":"Med J Aust"},{"key":"10.1016\/j.pharmr.2025.100058_bib340","doi-asserted-by":"crossref","first-page":"11077","DOI":"10.3748\/wjg.v21.i39.11077","article-title":"Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance","volume":"21","author":"St\u00e5l","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharmr.2025.100058_bib548","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-8993(93)90458-Y","article-title":"Lateral hypothalamic injections of glutamate kainic acid DL-\u03b1-amino-3-hydroxy-5-methyl-isoxazole propionic acid or N-methyl-D-aspartic acid rapidly elicit intense transient eating in rats","volume":"613","author":"Stanley","year":"1993","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmr.2025.100058_bib549","first-page":"E603","article-title":"GIP increases insulin receptor affinity and cellular sensitivity in adipocytes","volume":"249","author":"Starich","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmr.2025.100058_bib341","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156057","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.pharmr.2025.100058_bib342","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.celrep.2019.10.117","article-title":"Quantitative in vivo proteomics of metformin response in liver reveals AMPK-dependent and -independent signaling networks","volume":"29","author":"Stein","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.pharmr.2025.100058_bib343","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1463-1326.2006.00618.x","article-title":"Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes","volume":"9","author":"Stenl\u00f6f","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib344","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00213-016-4260-7","article-title":"Safety and tolerability of intranasal cocaine during phendimetrazine maintenance","volume":"233","author":"Stoops","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmr.2025.100058_bib345","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ijo.2013.225","article-title":"A comparative study of five centrally acting drugs on the pharmacological treatment of obesity","volume":"38","author":"Suplicy","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib346","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jhep.2005.06.008","article-title":"Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease","volume":"43","author":"Suzuki","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib553","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0303-7207(94)90162-7","article-title":"Relative quantitative analysis of glucagon receptor mRNA in rat tissues","volume":"105","author":"Svoboda","year":"1994","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100058_bib347","unstructured":"Symlin (pramlintide acetate) injection (2019) Package insert. US Food and Drug Administration. Revised December 2019. Accessed May 15, 2023. LP AP, Wilmington, DE."},{"key":"10.1016\/j.pharmr.2025.100058_bib349","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1507\/endocrj.EJ14-0147","article-title":"Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study","volume":"61","author":"Terauchi","year":"2014","journal-title":"Endocr J"},{"key":"10.1016\/j.pharmr.2025.100058_bib555","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/db18-1163","article-title":"Effects of Pioglitazone on glucose-dependent insulinotropic polypeptide-mediated insulin secretion and adipocyte receptor expression in patients with Type 2 diabetes","volume":"69","author":"Tharp","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib350","doi-asserted-by":"crossref","first-page":"E224","DOI":"10.1152\/ajpendo.00347.2016","article-title":"Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response","volume":"312","author":"Thondam","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib556","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.2337\/diab.42.11.1678","article-title":"Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor","volume":"42","author":"Thorens","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib351","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2211933120","article-title":"Metformin acts in the gut and induces gut-liver crosstalk","volume":"120","author":"Tobar","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100058_bib567","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.22.7.1137","article-title":"Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients","volume":"22","author":"Toft-Nielsen","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib352","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.amjcard.2005.03.053","article-title":"Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension","volume":"96","author":"Tonstad","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmr.2025.100058_bib353","unstructured":"Topamax (topiramate) tablets. (2023) Package insert. US Food and Drug Administration. Revised May 2023. Accessed May 15, 2023. Janssen Ortho, Gurabo, Puerto Rico."},{"key":"10.1016\/j.pharmr.2025.100058_bib354","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1463-1326.2005.00483.x","article-title":"X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance","volume":"7","author":"Toplak","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib355","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib356","unstructured":"Trokendi XR (topiramate) extended-release capsules. (2022) Package insert. US Food and Drug Administration. Revised October 2022. Accessed May 15, 2023. Catalent Pharma Solutions, Winchester, KY."},{"key":"10.1016\/j.pharmr.2025.100058_bib357","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1359\/jbmr.2002.17.3.521","article-title":"A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers","volume":"17","author":"Trovas","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pharmr.2025.100058_bib358","first-page":"726","article-title":"Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study","volume":"14","author":"Truant","year":"1972","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.pharmr.2025.100058_bib359","unstructured":"Trulicity (dulaglutide) injection (2022) Package insert. US Food and Drug Administration. Revised November 2022. Accessed May 15, 2023. Eli Lilly, Indianapolis, IN."},{"key":"10.1016\/j.pharmr.2025.100058_bib360","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/2150131912439893","article-title":"A pilot randomized trial comparing a commercial weight loss program with a clinic-based intervention for weight loss","volume":"3","author":"Tsai","year":"2012","journal-title":"J Prim Care Community Health"},{"key":"10.1016\/j.pharmr.2025.100058_bib541","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2265.1974.tb02820.x","article-title":"The effect of the intestinal polypeptides IRP and GIP on sinlin release and glucose tolerance in the baboon","volume":"3","author":"Turner","year":"1974","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharmr.2025.100058_bib542","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100058_bib543","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3181\/00379727-102-25338","article-title":"Glucagon antibodies and their use for immunoassay for glucagon","volume":"102","author":"Unger","year":"1959","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib361","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1210\/jc.2015-3906","article-title":"Mechanisms of action of liraglutide in patients with type 2 diabetes treated with high-dose insulin","volume":"101","author":"Vanderheiden","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib362","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.4049\/jimmunol.1401149","article-title":"Long-acting glucose-dependent insulinotropic polypeptide ameliorates obesity-induced adipose tissue inflammation","volume":"193","author":"Varol","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmr.2025.100058_bib363","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib364","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc20-1843","article-title":"Liraglutide increases the catabolism of apolipoprotein B100-containing lipoproteins in patients with type 2 diabetes and reduces proprotein convertase subtilisin\/kexin type 9 expression","volume":"44","author":"Verg\u00e8s","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib365","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1161\/ATVBAHA.118.310990","article-title":"Liraglutide reduces postprandial hyperlipidemia by increasing ApoB48 (apolipoprotein B48) catabolism and by reducing ApoB48 production in patients with type 2 diabetes mellitus","volume":"38","author":"Verg\u00e8s","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2025.100058_bib366","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib550","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","article-title":"Topiramate-induced weight loss: a review","volume":"95","author":"Verrotti","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.pharmr.2025.100058_bib367","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib551","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dc06-2593","article-title":"Liraglutide a long-acting human glucagon-like peptide-1 analog given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes","volume":"30","author":"Vilsb\u00f8ll","year":"2007","journal-title":"Diabetes care"},{"key":"10.1016\/j.pharmr.2025.100058_bib552","article-title":"VI-0521 (QNEXA) Advisory Committee Briefing Document (NDA 022580)","year":"2012","journal-title":"Endocrinologic and Metabolic Drugs Advisory Committee Meeting; 2012, February 22"},{"key":"10.1016\/j.pharmr.2025.100058_bib368","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"Vos","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.pharmr.2025.100058_bib369","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib554","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib370","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib371","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/(SICI)1098-108X(199709)22:2<203::AID-EAT13>3.0.CO;2-1","article-title":"A multicenter evaluation of a proprietary weight loss program for the treatment of marked obesity: a five-year follow-up","volume":"22","author":"Wadden","year":"1997","journal-title":"Int J Eat Disord"},{"key":"10.1016\/j.pharmr.2025.100058_bib372","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib373","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib374","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/oby.22359","article-title":"Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial","volume":"27","author":"Wadden","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmr.2025.100058_bib375","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0140-6736(00)03643-6","article-title":"Brain dopamine and obesity","volume":"357","author":"Wang","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100058_bib557","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2017.28","article-title":"The effect of glucose-dependent insulinotropic polypeptide (GIP) variants on visceral fat accumulation in Han Chinese populations","volume":"7","author":"Wang","year":"2017","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib376","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/chi.2018.0043","article-title":"Metformin in the management of childhood obesity: a randomized control trial","volume":"14","author":"Warnakulasuriya","year":"2018","journal-title":"Child Obes"},{"key":"10.1016\/j.pharmr.2025.100058_bib377","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0021-9258(18)86579-6","article-title":"Studies in the metabolism changes induced by adminnistration of guanidine bases","volume":"33","author":"Watanabe","year":"1918","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100058_bib378","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41423-021-00791-9","article-title":"Metabolism of tissue macrophages in homeostasis and pathology","volume":"19","author":"Wculek","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.pharmr.2025.100058_bib558","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/ijo.2008.148","article-title":"Functional expression of glucose-dependent insulinotropic polypeptide receptors is couple to differentiation in a human adipocyte model","volume":"32","author":"Weaver","year":"2008","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.pharmr.2025.100058_bib379","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib380","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12624","article-title":"A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity","volume":"15","author":"Weghuber","year":"2020","journal-title":"Pediatr Obes"},{"key":"10.1016\/j.pharmr.2025.100058_bib381","unstructured":"Wegovy (semaglutide) injection (2022) Package insert. US Food and Drug Administration. Revised December 2022. Accessed May 15, 2023. Novo Nordisk, Bagsvaerd, Denmark."},{"key":"10.1016\/j.pharmr.2025.100058_bib382","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.7164\/antibiotics.40.1081","article-title":"Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity","volume":"40","author":"Weibel","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.pharmr.2025.100058_bib383","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.1992.68","article-title":"Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib384","doi-asserted-by":"crossref","first-page":"e832","DOI":"10.1210\/clinem\/dgad100","article-title":"Five-year weight loss maintenance with obesity pharmacotherapy","volume":"108","author":"Weintraub","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib559","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.2337\/diabetes.53.4.1038","article-title":"Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells","volume":"53","author":"Wendt","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib560","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1073\/pnas.84.11.3881","article-title":"Amyloid fibrils in human insulinoma and islets of langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells","volume":"84","author":"Westermark","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100058_bib385","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib386","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib561","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-1211(97)00045-4","article-title":"Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride current in murine brain neurons and increases seizure threshold","volume":"28","author":"White","year":"1997","journal-title":"Epilepsy Res"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2025.100058_bib562","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","article-title":"Topiramate modulates GABA-evoked current in murine cortical neuronos by a nonbenzodiazepine mechanism","volume":"41","author":"White","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmr.2025.100058_bib387","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.physbeh.2010.04.012","article-title":"Central amylin acts as an adiposity signal to control body weight and energy expenditure","volume":"101","author":"Wielinga","year":"2010","journal-title":"Physiol Behav"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2025.100058_bib388","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199958001-00009","article-title":"The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms","volume":"58","author":"Wiernsperger","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.pharmr.2025.100058_bib389","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects","volume":"28","author":"Wilding","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.pharmr.2025.100058_bib390","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100058_bib391","first-page":"231","article-title":"Weight reduction in osteoarthritis using phentermine","volume":"225","author":"Willims","year":"1981","journal-title":"Practitioner"},{"key":"10.1016\/j.pharmr.2025.100058_bib392","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.5665\/sleep.2204","article-title":"A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine\/topiramate for the treatment of obstructive sleep apnea in obese adults","volume":"35","author":"Winslow","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.pharmr.2025.100058_bib393","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib394","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21032\/jhis.2018.43.4.290","article-title":"Meta-analysis of change in weight and heart rate for phentermine in obesity","volume":"43","author":"Woo","year":"2018","journal-title":"J Health Inform Stat"},{"key":"10.1016\/j.pharmr.2025.100058_bib395","series-title":"The Asia-Pacific Perspective: Redefining Obesity and Its Treatment","first-page":"55","year":"2000"},{"key":"10.1016\/j.pharmr.2025.100058_bib396","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100058_bib397","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2020.07.034","article-title":"Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice","volume":"159","author":"Xanthakos","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib398","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.immuni.2021.05.004","article-title":"Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation","volume":"54","author":"Xian","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.pharmr.2025.100058_bib399","unstructured":"Xenical (orlistat) capsule. (2022) Package insert. US Food and Drug Administration. Revised December 2022. Accessed May 15, 2023. H2-Pharma, Montgomery, AL."},{"key":"10.1016\/j.pharmr.2025.100058_bib400","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s42255-024-00999-9","article-title":"Lac-Phe mediates the effects of metformin on food intake and body weight","volume":"6","author":"Xiao","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib401","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41419-021-04235-0","article-title":"Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt","volume":"12","author":"Xiong","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pharmr.2025.100058_bib402","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmr.2025.100058_bib403","author":"Yanovski"},{"key":"10.1016\/j.pharmr.2025.100058_bib405","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","article-title":"Long-term drug treatment for obesity: a systematic and clinical review","volume":"311","author":"Yanovski","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100058_bib406","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0149-7634(02)00041-6","article-title":"Opioid peptides and the control of human ingestive behaviour","volume":"26","author":"Yeomans","year":"2002","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmr.2025.100058_bib407","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104684","article-title":"Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE\u22173-Leiden.CETP mice","volume":"93","author":"Ying","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmr.2025.100058_bib408","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpeds.2020.03.038","article-title":"Glomerular hyperfiltration is associated with liver disease severity in children with nonalcoholic fatty liver disease","volume":"222","author":"Yodoshi","year":"2020","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmr.2025.100058_bib409","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2025.100058_bib410","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpeds.2018.11.021","article-title":"Prevalence of nonalcoholic fatty liver disease in children with obesity","volume":"207","author":"Yu","year":"2019","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmr.2025.100058_bib563","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113326","article-title":"GLP-1 and GIP receptors signal through distinct \u03b2-arrestin 2-dependent pathways to regulate pancreatic \u03b2 cell function","volume":"42","author":"Za\u00efmia","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.pharmr.2025.100058_bib411","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"Zelber-Sagi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2025.100058_bib412","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmet.2016.09.003","article-title":"Metformin activates AMPK through the lysosomal pathway","volume":"24","author":"Zhang","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2025.100058_bib413","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1528-1157.2000.tb02173.x","article-title":"Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate","volume":"41","author":"Zhang","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmr.2025.100058_bib564","article-title":"Increasing prevalence of NAFLD\/NASH among children adolescents and young adults from 1990 to 2017 a population-based observational study","volume":"11","author":"Zhang","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.pharmr.2025.100058_bib414","article-title":"Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2025.100058_bib415","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/17512433.2022.2117152","article-title":"Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis","volume":"15","author":"Zhao","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100058_bib565","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2337\/db06-1454","article-title":"Zinc not insulin regulates the rat alpha-cell response to hypoglycemia in vivo","volume":"56","author":"Zhou","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2025.100058_bib416","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.107.132654","article-title":"Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels","volume":"324","author":"Zolkowska","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib417","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/jpet.106.101618","article-title":"Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease","volume":"318","author":"Zolkowska","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2025.100058_bib418","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106057","article-title":"Oral metformin transiently lowers post-prandial glucose response by reducing the apical expression of sodium-glucose co-transporter 1 in enterocytes","volume":"26","author":"Zubiaga","year":"2023","journal-title":"iScience"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T23:09:08Z","timestamp":1759964948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725074666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":542,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0031699725074666"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100058","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiobesity medications in adult and pediatric obesity and metabolic dysfunction\u2013associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100058"}}